Compare Danaher Corporation (DHR) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs New York Times Co — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while New York Times Co trades at $63.73 (market cap $10.28B). The key difference: Danaher Corporation is far larger — about 14.2× New York Times Co's market cap, and New York Times Co pays the higher dividend (1.44%). Which is the better fit depends on your goals.
| DHR | NYT | |
|---|---|---|
Market Cap | $145.83B | $10.28B |
Sector | Health | Media |
52-Week High | $242.05 | $85.86 |
52-Week Low | $161.91 | $54.66 |
Enterprise Value | $168.04B | $9.67B |
Dividend Yield | 0.77% | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
The New York Times (NYT) trades at $63.93, down 1.34% amid bearish technical signals despite strong Q2 2026 earnings beats. Revenue growth continues with 2025 revenue reaching $2.82B and net income margin expanding to 12.17%. The stock faces technical pressure with RSI at oversold levels near key support at $62-63, while analyst consensus remains cautious with 65% hold ratings.
NYT demonstrates solid fundamental growth with expanding profitability and digital subscription strength, but faces near-term headwinds from slowing subscriber growth and technical weakness. The $77.50 consensus price target suggests 21% upside potential, though execution risks and competitive pressures warrant monitoring for current investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
